A Horvath1, P Dziechciarz, H Szajewska. 1. Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland. andrea.hania@gmail.com
Abstract
BACKGROUND: Problems with the standard triple treatment recommended for Helicobacter pylori eradication therapy include unsatisfactory (less than 80%) eradication rates among children. AIM: To assess the evidence for sequential therapy compared with triple therapy on H. pylori eradication rates in children. METHODS: The Cochrane Library, MEDLINE and EMBASE databases were searched in May 2012, with no language restrictions, as were abstracts from major gastroenterology conferences, for randomised controlled trials (RCTs) comparing sequential therapy with standard triple therapy for H. pylori eradication. Additional references were obtained from reviewed articles. Authors were contacted for extra information. Dichotomous data were pooled to obtain the relative risk (RR) of the eradication rate, with a 95% CI. RESULTS: Ten RCTs involving a total of 857 children aged 3-18 years met the inclusion criteria. Of the 409 patients in the sequential therapy group, 318 (78%, 95% CI 73-82) experienced eradication compared with 314 of the 444 patients (71%, 95% CI 66-75) in the standard triple therapy group (RR 1.14, 95% CI 1.06-1.23, number needed to treat 15; fixed-effects model). Sequential therapy was superior to 7-day standard triple therapy, but was not significantly better than 10-day or 14-day triple therapy. There were no significant differences between groups in the risk of adverse effects. CONCLUSIONS: The pooled evidence suggests that 10-day sequential therapy compared with standard triple therapy may be considered as an option for increasing the eradication rates in children; however, it is still less than desired.
BACKGROUND: Problems with the standard triple treatment recommended for Helicobacter pylori eradication therapy include unsatisfactory (less than 80%) eradication rates among children. AIM: To assess the evidence for sequential therapy compared with triple therapy on H. pylori eradication rates in children. METHODS: The Cochrane Library, MEDLINE and EMBASE databases were searched in May 2012, with no language restrictions, as were abstracts from major gastroenterology conferences, for randomised controlled trials (RCTs) comparing sequential therapy with standard triple therapy for H. pylori eradication. Additional references were obtained from reviewed articles. Authors were contacted for extra information. Dichotomous data were pooled to obtain the relative risk (RR) of the eradication rate, with a 95% CI. RESULTS: Ten RCTs involving a total of 857 children aged 3-18 years met the inclusion criteria. Of the 409 patients in the sequential therapy group, 318 (78%, 95% CI 73-82) experienced eradication compared with 314 of the 444 patients (71%, 95% CI 66-75) in the standard triple therapy group (RR 1.14, 95% CI 1.06-1.23, number needed to treat 15; fixed-effects model). Sequential therapy was superior to 7-day standard triple therapy, but was not significantly better than 10-day or 14-day triple therapy. There were no significant differences between groups in the risk of adverse effects. CONCLUSIONS: The pooled evidence suggests that 10-day sequential therapy compared with standard triple therapy may be considered as an option for increasing the eradication rates in children; however, it is still less than desired.
Authors: Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: Carlo A Fallone; Alan N Barkun; Andrew Szilagyi; Karl M Herba; Maida Sewitch; Myriam Martel; Stefanie S Fallone Journal: Can J Gastroenterol Date: 2013-07 Impact factor: 3.522
Authors: Marco Manfredi; Pierpacifico Gismondi; Valentina Maffini; Barbara Bizzarri; Fabiola Fornaroli; Carmen Madia; Antonino Salerno; A Marta Cangelosi; Gian Luigi de'Angelis Journal: Gastroenterol Res Pract Date: 2015-05-06 Impact factor: 2.260